Northwest Biotherapeutics Inc., of Bethesda, Md., said it launched a phase II program combining its personalized immune therapy Dcvax-L and PD-1 inhibitor Keytruda (pembrolizumab, Merck & Co. Inc.) for colorectal cancer with liver metastases. The investigator-initiated study will treat patients for up to six months with the combination regimen, with a long-term follow-up regarding patient survival.